Traws Pharma Reports Director/Officer Changes
Ticker: TRAW · Form: 8-K · Filed: Oct 17, 2025 · CIK: 1130598
| Field | Detail |
|---|---|
| Company | Traws Pharma, Inc. (TRAW) |
| Form Type | 8-K |
| Filed Date | Oct 17, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $3.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, governance, officer-appointment, director-election
Related Tickers: TRWS
TL;DR
Traws Pharma (TRWS) filed an 8-K detailing board and exec changes effective Oct 12.
AI Summary
Traws Pharma, Inc. (formerly Onconova Therapeutics, Inc.) filed an 8-K on October 17, 2025, reporting changes effective October 12, 2025. The filing covers the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements for certain officers. The company is incorporated in Delaware and its fiscal year ends on December 31.
Why It Matters
Changes in a company's board of directors and executive officers can signal shifts in strategy, governance, or operational focus.
Risk Assessment
Risk Level: medium — Changes in key personnel and governance can introduce uncertainty and potential strategic shifts.
Key Players & Entities
- Traws Pharma, Inc. (company) — Registrant
- Onconova Therapeutics, Inc. (company) — Former company name
- October 12, 2025 (date) — Effective date of reported events
- October 17, 2025 (date) — Filing date of the 8-K
- Delaware (jurisdiction) — State of incorporation
FAQ
What specific roles or directorships changed at Traws Pharma, Inc.?
The filing indicates changes related to the 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers,' but the specific names and roles are not detailed in this excerpt.
Were there any new compensatory arrangements disclosed for officers?
The filing lists 'Compensatory Arrangements of Certain Officers' as an item covered, but the details of these arrangements are not provided in this summary.
When did Traws Pharma, Inc. officially change its name from Onconova Therapeutics, Inc.?
The provided text shows multiple previous names for Onconova Therapeutics, Inc. with name change dates in 2009 and 2000, but does not specify the exact date Traws Pharma, Inc. became the current name.
What is the primary business of Traws Pharma, Inc. according to the SIC code?
The Standard Industrial Classification (SIC) code listed is 2834, which corresponds to 'PHARMACEUTICAL PREPARATIONS'.
Where is Traws Pharma, Inc. headquartered?
The company's business and mailing address is listed as 12 Penns Trail, Newtown, PA 18940.
Filing Stats: 531 words · 2 min read · ~2 pages · Grade level 13.1 · Accepted 2025-10-17 17:03:50
Key Financial Figures
- $3.01 — . The Options have an exercise price of $3.01 per share (the closing price of the Com
Filing Documents
- tm2528641d1_8k.htm (8-K) — 23KB
- 0001104659-25-100455.txt ( ) — 182KB
- tmb-20251012.xsd (EX-101.SCH) — 3KB
- tmb-20251012_lab.xml (EX-101.LAB) — 33KB
- tmb-20251012_pre.xml (EX-101.PRE) — 22KB
- tm2528641d1_8k_htm.xml (XML) — 3KB
02 Departure of Directors or Certain
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 12, 2025, the Compensation Committee of the Board of Directors of Traws Pharma, Inc. (the "Company") approved the grant of options to purchase shares of Company common stock (collectively, the "Options") to the Company's executive officers, as follows: 64,839 Options to Iain Dukes, the Company's Chief Executive Officer; 32,406 Options to Charles Parker, the Company's Chief Financial Officer; 32,406 Options to C. David Pauza, the Company's Chief Science Officer, Virology; 32,406 Options to Robert Redfield, the Company's Chief Medical Officer; and 22,435 Options to Nikolay Savchuk, the Company's Chief Operating Officer. The Options have an exercise price of $3.01 per share (the closing price of the Company's common stock on October 10, 2025), have a ten year term, and vest in full on the first anniversary of the grant date, subject to the respective recipient's continued service to the Company through the vesting date. The Options were granted under the Company's Amended and Restated 2021 Incentive Compensation Plan.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 17, 2025 TRAWS PHARMA, INC. By: /s/ Iain Dukes Iain Dukes Chief Executive Officer